文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

法国和意大利临床环境中多替拉韦方案治疗失败者整合酶耐药评估

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究回顾性分析467例接受含多替拉韦方案治疗失败的HIV-1感染者,评估整合酶耐药突变及其预测因素。失败时12.4%携带≥1个整合酶主要耐药突变,既往暴露于整合酶链转移抑制剂者耐药率显著高于未暴露者(21.2% vs 3.9%,P<0.001)。既往未暴露于INSTI及伴随药物GSS≥2与整合酶耐药风险负相关。

要点

  • 多替拉韦治疗失败者中12.4%检出≥1个整合酶主要耐药突变。
  • INSTI经治者耐药率21.2%,显著高于初治者的3.9%(P<0.001)。
  • 失败时89.5%个体病毒株对多替拉韦和比克替拉韦完全敏感,85.0%对所有INSTI敏感。

核心结论

  • 在真实世界中大批多替拉韦治疗失败者中,整合酶耐药率低,且主要与既往第一代INSTI暴露相关。
  • 整合酶耐药监测对维持INSTI类药物未来疗效仍至关重要。

研究设计与样本

  • 回顾性分析467例接受含多替拉韦联合抗逆转录病毒治疗失败的HIV-1感染经治个体。
  • 在多替拉韦失败时进行血浆基因型耐药检测,评估主要耐药突变及伴随药物基因型敏感性评分。
  • 采用logistic回归分析与整合酶链转移抑制剂耐药风险相关的因素。

主要发现

  • 失败时个体接受多替拉韦中位时间11个月(IQR 5-20),52%从未暴露于INSTI,10.7%处于一线方案。
  • 58例(12.4%)检出≥1个INSTI主要耐药突变;INSTI暴露者46例(21.2%)vs INSTI初治者9例(3.9%),P<0.001。
  • 最常见主要耐药突变为N155H(5.4%),其次G140S(4.5%)和Q148H(4.3%)。
  • 失败时89.5%个体病毒株对多替拉韦和比克替拉韦完全敏感,85.0%对所有INSTI敏感。
  • 多替拉韦前无INSTI暴露[OR 0.35(0.16-0.78),P<0.010]及伴随药物GSS≥2[OR 0.09(0.04-0.23),P<0.001]与失败时INSTI耐药负相关。

关键数值与推荐

  • INSTI暴露者INSTI耐药率21.2% vs INSTI初治者3.9%(P<0.001)。
  • 失败时对多替拉韦和比克替拉韦完全敏感者占89.5%,对所有INSTI敏感者占85.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This work aims to evaluate integrase resistance and its predictors in HIV-1 infected combined antiretroviral therapy (cART) experienced individuals failing a dolutegravir-based regimen. METHODS: Major resistance mutations (MRM) and genotypic susceptibility score (GSS) of dolutegravir companion drugs were evaluated on plasma genotypic resistance test (GRT) performed at dolutegravir failure. Logistic regression was used to evaluate factors associated to the risk of integrase strand-transfer inhibitors (INSTI)-resistance at dolutegravir failure. RESULTS: We retrospectively analysed 467 individuals. At failure GRT, individuals had been under dolutegravir for a median (IQR) time of 11 (5-20) months; around half of them had never been exposed to INSTI (52%) and 10.7% were at first-line regimen. Fifty-eight (12.4%) individuals showed ≥1 INSTI MRM. Among them, people INSTI-exposed showed significantly higher prevalence of INSTI resistance compared to those who were INSTI naïve [46 (21.2%) versus 9 (3.9%), P < 0.001].N155H was the most prevalent MRM (5.4%), followed by G140S (4.5%) and Q148H (4.3%). These MRM were more probably present in INSTI-experienced individuals compared to those INSTI naïve. Despite failure, 89.5% of individuals harboured viral strains fully susceptible to dolutegravir and bictegravir and 85.0% to all INSTI. No INSTI exposure before receiving dolutegravir [OR: 0.35 (0.16-0.78), P < 0.010] and a GSS for companion drugs ≥2 (OR: 0.09 [0.04-0.23], P < 0.001) were negatively associated with INSTI resistance at failure. CONCLUSIONS: In a large set of individuals failing dolutegravir in real-life, INSTI resistance was low and mainly related to previous first-generation INSTI exposure. Surveillance of integrase resistance remains crucial to preserve efficacy of INSTI class in the future.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Armenia D, Santoro MM, Charpentier C, et al. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. J Antimicrob Chemother. 2023. PMID: 37258034. doi:10.1093/jac/dkad101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。